TrialAdvances in therapy2025

Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 Trial.

Yan Zhao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.